61 results
POS AM
SYRE
Spyre Therapeutics Inc.
26 Mar 24
Prospectus update (post-effective amendment)
6:30pm
, which was attributable to the PEACE Phase 3 trial and BLA package.
Research and Development Expenses. Our research and development expenses incurred … trial and BLA package of the Immedica Agreement. For the year ended December 31, 2021, we recognized $18.7 million of license and development fee
POS AM
SYRE
Spyre Therapeutics Inc.
14 Mar 24
Prospectus update (post-effective amendment)
4:12pm
of development fee revenue in connection with the Immedica Agreement, which was attributable to the PEACE Phase 3 trial and BLA package.
Research … of development fee revenue allocated to the PEACE Phase 3 trial and BLA package of the Immedica Agreement. For the year ended December 31, 2021, we
POS AM
SYRE
Spyre Therapeutics Inc.
5 Mar 24
Prospectus update (post-effective amendment)
5:15pm
$2.3 million of development fee revenue in connection with the Immedica Agreement, which was attributable to the PEACE Phase 3 trial and BLA package … of development fee revenue allocated to the PEACE Phase 3 trial and BLA package of the Immedica Agreement. For the year ended December 31, 2021, we recognized
8-K
EX-99.1
b26pjc0t iqmx9rm3v4b
15 Nov 23
Other Events
5:14pm
8-K
EX-99.2
9z6pkyxhzhk9
15 Nov 23
Other Events
5:14pm
PRER14A
q22zkan3e3
6 Oct 23
Preliminary revised proxy
9:40pm